Literature DB >> 2533598

Adoptive immunotherapy with interleukin-2 (IL-2) results in diminished IL-2 production by stimulated peripheral blood lymphocytes.

R Kradin1, J Kurnick, J Gifford, C Pinto, F Preffer, D Lazarus.   

Abstract

We examined the responses of peripheral blood lymphocytes (PBL) to a panel of T-cell mitogens in patients receiving adoptive transfers of tumor-infiltrating lymphocytes and continuous infusions of interleukin-2 (IL-2) for treatment of advanced cancer. All patients showed diminished proliferative responses to soluble and alloantigens, lectins, anti-CD3, and IL-2 during therapy. The non-major histocompatibility complex (MHC)-restricted cytolytic activities of PBL were increased by treatment and were further augmented by IL-2 in vitro. The expression of approximately 55-kd low-affinity IL-2 receptors (IL-2R) by PBL increased during treatment but functional IL-2R were simultaneously down-regulated. Proliferative responses were partially restored to pretreatment levels when PBL were costimulated with recombinant IL-2 and mitogens. Lectin stimulation of PBL produced little IL-2 secretion during treatment, while IFN-gamma secretion persisted. We conclude that infusions of IL-2 down-regulate the expression of functional IL-2R, decrease the secretion of IL-2, and lead to decreased mitogen responses by PBL.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2533598     DOI: 10.1007/bf00917102

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  47 in total

1.  Functional characterization of T lymphocytes propagated from human lung carcinomas.

Authors:  J T Kurnick; R L Kradin; R Blumberg; E E Schneeberger; L A Boyle
Journal:  Clin Immunol Immunopathol       Date:  1986-03

2.  Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.

Authors:  R L Kradin; L A Boyle; F I Preffer; R J Callahan; M Barlai-Kovach; H W Strauss; S Dubinett; J T Kurnick
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

3.  IL-4 is required to generate and sustain in vivo IgE responses.

Authors:  F D Finkelman; I M Katona; J F Urban; J Holmes; J Ohara; A S Tung; J V Sample; W E Paul
Journal:  J Immunol       Date:  1988-10-01       Impact factor: 5.422

4.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

5.  The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Authors:  N S Rosenthal; J A Hank; P C Kohler; D Z Minkoff; K H Moore; R Bechhofer; R Hong; B Storer; P M Sondel
Journal:  J Biol Response Mod       Date:  1988-04

6.  IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses.

Authors:  F D Finkelman; I M Katona; T R Mosmann; R L Coffman
Journal:  J Immunol       Date:  1988-02-15       Impact factor: 5.422

7.  Internalization of interleukin 2 is mediated by the beta chain of the high-affinity interleukin 2 receptor.

Authors:  R J Robb; W C Greene
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

8.  Sequential expression of genes involved in human T lymphocyte growth and differentiation.

Authors:  M Krönke; W J Leonard; J M Depper; W C Greene
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

9.  The interleukin 2 receptor. Functional consequences of its bimolecular structure.

Authors:  H M Wang; K A Smith
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

10.  Accessory cell-T lymphocyte interactions. Antigen-dependent and -independent clustering.

Authors:  K Inaba; R M Steinman
Journal:  J Exp Med       Date:  1986-02-01       Impact factor: 14.307

View more
  4 in total

1.  Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2.

Authors:  P De Paoli; S Zanussi; L Caggiari; M T Bortolin; M D'Andrea; C Simonelli; U Tirelli
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

2.  Melanoma antigen recognition by tumour-infiltrating T lymphocytes (TIL): effect of differential expression of melan-A/MART-1.

Authors:  T Ramirez-Montagut; D M Andrews; A Ihara; S Pervaiz; F Pandolfi; P J Van Den Elsen; R Waitkus; L A Boyle; M Hishii; J T Kurnick
Journal:  Clin Exp Immunol       Date:  2000-01       Impact factor: 4.330

Review 3.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

Review 4.  Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.

Authors:  Hanren Dai; Yao Wang; Xuechun Lu; Weidong Han
Journal:  J Natl Cancer Inst       Date:  2016-01-27       Impact factor: 13.506

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.